3D Ephemeris to support time orientation in Alzheimer's
Official title: Evaluation of the Feasibility, Practicality, and Interest of the 3D Ephemeris, a Tool for the Rehabilitation of Temporal Orientation Disorder in People With Alzheimer's Disease or Related Dementia: Monocentric Observational Pilot Study
Run by Assistance Publique - Hôpitaux de Paris · NCT06824142 · Data updated 2026-11-12
This project tests whether a 3D calendar device called the Ephéméride 3D can help people aged 65 and older with mild to moderate Alzheimer's or related dementias stay oriented to the day and time during hospitalization.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 65 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Champcueil) |
| Status | Recruiting |
| Started | April 25, 2025 |
| Main results expected | March 30, 2026 |
| Study ends | March 30, 2026 |
| Registry record updated | January 15, 2026 |
| Trial ID | NCT06824142 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people aged 65 or older with mild to moderate Alzheimer’s or related dementia who show temporal orientation errors on the MMSE, can read French, and do not have visual blindness or disruptive behavioral disorders.
✕Probably not a fit
Patients with severe dementia, unexplained acute confusion, visual blindness, inability to read French, or significant disruptive behaviors are unlikely to benefit from this device.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot is an observational, real-world implementation of a prototype adapted external aid (Ephéméride 3D) to support temporal orientation in older adults with Alzheimer’s disease or related dementias. Occupational therapists will identify participants with temporal orientation impairments using validated tools such as MMSE temporal items and introduce the device in a hospital setting. The study enrolls patients aged 65 and over with mild to moderate cognitive impairment (MMSE >20 or 10–20) who can read French, excluding those with visual blindness, unexplained confusion, or disruptive behavioral disorders. Outcomes include feasibility, patient and therapist interest, and changes in temporal orientation performance measured before and after use of the device.
Why it matters
Potential benefit: If successful, the device could reduce temporal disorientation and related distress during hospitalization and help patients keep track of the day and time.
How similar studies have gone: External orientation aids such as calendars and clocks have produced mixed or limited benefits in dementia care, and the 3D Ephéméride prototype is a novel approach that is not yet proven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient ≥ 65 years old. * Patient presenting with temporal orientation impairment during the MMSE test. * Patient with an MMSE score above 20 (mild stage) or a score between 10 and 20 (moderate stage). * Patient who has not expressed any objection. Exclusion Criteria: * Presence of one or more disruptive behavioral disorders. * Presence of confusion of unknown origin. * Visual blindness. * Inability to read or understand French.
Where it's running
-
Hôpital Georges Clemenceau
Champcueil, France Recruiting
Study contacts
- Study coordinator: REBOURS Gwénaëlle, Occupational therapist
- Email: gwenaelle.rebours@aphp.fr
- Phone: +331 69 23 21 33
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood biomarker cohort for memory disorders in older adults
This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.
-
Tau changes after hip or knee replacement surgery
Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.
-
Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Mild Alzheimer's Dementia
This study will test whether a low-dose brain radiation treatment using HeLaXON helps people with mild Alzheimer's dementia improve or stabilize thinking and daily function.
-
Cervical lymphatic surgery to see if it helps people with mild Alzheimer’s
We’re testing a surgical approach in people with mild Alzheimer’s to see if creating alternative neck lymph drainage routes can affect brain biomarkers and daily function.
-
Transcranial random noise stimulation for behavioral and psychological symptoms in Alzheimer's disease
This trial tests whether high-frequency transcranial random noise stimulation can help people with early Alzheimer's disease who have BPSD, compared to a sham treatment.
-
Testing LY4405094 in healthy people and people with Alzheimer’s disease
This study tests LY4405094 to see if it is safe and how it behaves in the body, including how it reaches the brain fluid in healthy participants and how it affects a brain protein in people with Alzheimer's disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.